{"id":6159,"date":"2025-09-10T09:29:21","date_gmt":"2025-09-10T07:29:21","guid":{"rendered":"https:\/\/www.ehc.eu\/uncategorized-hr\/ehc-poziva-eu-da-doda-von-willebrandov-faktor-na-popis-kriticnih-lijekova\/"},"modified":"2026-04-02T16:31:50","modified_gmt":"2026-04-02T14:31:50","slug":"ehc-poziva-eu-da-doda-von-willebrandov-faktor-na-popis-kriticnih-lijekova","status":"publish","type":"post","link":"https:\/\/www.ehc.eu\/hr\/uncategorized-hr\/ehc-poziva-eu-da-doda-von-willebrandov-faktor-na-popis-kriticnih-lijekova\/","title":{"rendered":"EHC poziva EU da doda von Willebrandov faktor na popis kriti\u010dnih lijekova"},"content":{"rendered":"<!-- hero -->\t<section   class=\"subpage-hero bg-white\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"relative z-10\">\n\t\t\t\t<div class=\"pt-16 lg:pt-24 pb-24 lg:pb-32\">\n\t\t\t\t\t<div class=\"row justify-between gap-10 lg:gap-0 mt-10 text-center lg:text-left\">\n\t\t\t\t\t\t<div class=\"w-full lg:w-6\/12 lg:self-center\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"title h2\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t\t<p class=\"text-[115%]\">EHC poziva EU da doda von Willebrandov faktor na popis kriti\u010dnih lijekova<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<figure class=\"absolute size-[41.8rem] lg:size-[82.8rem] bottom-[-10%] right-[-10rem] lg:right-[-5%] image-contain opacity-100 skip-lazy\" data-parallax>\n\t\t\t\t\t<img decoding=\"async\" loading=\"eager\" src=\"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/themes\/cbd\/img\/content-logo-colorfull-2.svg\" alt=\"content-logo-colorfull\">\n\t\t\t\t<\/figure>\n\t\t\t\t\t\t<\/section>\n<!-- overview -->\t<section   class=\"s-overlay-img s-padding bg-red\">\n\t\t<div class=\"container\">\n\t\t\t<div class=\"row w-full lg:flex-row justify-between text-center lg:text-left gap-14 lg:gap-0 relative z-10\">\n\t\t\t\t\t\t\t\t<div class=\"w-full lg:py-10\">\n\t\t\t\t\t<div class=\"bg-white min-h-full py-12 px-10 lg:py-24 lg:pl-24 xl:pl-44 relative radius-20 z-10\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"content mt-8\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<p><!-- wp:paragraph --><\/p>\n<p>EHC poziva <a href=\"https:\/\/www.ema.europa.eu\/en\/homepage\" target=\"_blank\" rel=\"noopener\"><strong>Europsku agenciju za lijekove (EMA)<\/strong><\/a> da uklju\u010di <strong>von Willebrandov faktor (VWF) na Popis kriti\u010dnih lijekova Unije<\/strong>, isti\u010du\u0107i hitnu potrebu za za\u0161titom <strong>pacijenata s <a href=\"https:\/\/community.ehc.eu\/focus-area\/von-willebrand-disease-vwd\/\" target=\"_blank\" rel=\"noopener\">von Willebrandovom bole\u0161\u0107u (VWD).<\/a><\/strong><\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>VWD poga\u0111a izme\u0111u 0,6% i 1,3% populacije, \u0161to ga \u010dini naj\u010de\u0161\u0107im nasljednim poreme\u0107ajem krvarenja. Za pacijente s tipom 3 VWD i mnoge s tipom 2, VWF predstavlja terapiju koja spa\u0161ava \u017eivot kada alternativni tretmani poput desmopresina nisu u\u010dinkoviti. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Bez pouzdanog pristupa VWF-u, pacijenti se suo\u010davaju s po \u017eivot opasnim epizodama krvarenja, pove\u0107anim hospitalizacijama i potencijalno smrtonosnim ishodima. Trenutni nedostaci ne ugro\u017eavaju samo \u017eivote pacijenata, ve\u0107 i pove\u0107avaju tro\u0161kove zdravstvene skrbi kroz hitne intervencije i produ\u017eene bolni\u010dke boravke. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Iako desmopresin i dalje ostaje opcija za neke pacijente s VWD tipom 1, on ne mo\u017ee biti sveobuhvatno rje\u0161enje za cijeli spektar slu\u010dajeva VWD-a. Uklju\u010divanje VWF-a na popis kriti\u010dnih lijekova pokazalo bi predanost EU-a pravednoj skrbi za rijetke bolesti i oja\u010dalo spremnost Europe na nesta\u0161ice lijekova. <\/p>\n<p><!-- \/wp:paragraph --> <!-- wp:paragraph --><\/p>\n<p>Dodavanje VWF-a na ovaj popis predstavlja klju\u010dni korak prema osiguravanju da nijedan pacijent ne pati nepotrebno zbog nesta\u0161ica lijekova koji se mogu sprije\u010diti.<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"bottom mt-12\" data-scroll data-fade-up>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.ehc.eu\/wp-content\/uploads\/2025\/09\/EHC-statement-on-VWF-inclusion.pdf\" target=\"_blank\" class=\"btn with-icon\">\n\t\t\t\t\t\t\t\t\t<span>Read the full EHC statement <\/span>\n\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/section>\n\n<p><\/p>\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EHC poziva Europsku agenciju za lijekove da uklju\u010di von Willebrandov faktor na Savezni popis kriti\u010dnih lijekova, isti\u010du\u0107i hitnu potrebu za za\u0161titom pacijenata s von Willebrandovom bole\u0161\u0107u.<\/p>\n","protected":false},"author":4,"featured_media":4831,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[98,55],"tags":[136,211,129,212],"class_list":["post-6159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-svijest","category-uncategorized-hr","tag-kampanja","tag-popis-kriticnih-lijekova-eu-a","tag-stajaliste","tag-vwd"],"acf":[],"jetpack_featured_media_url":"https:\/\/etngbd86n6b.exactdn.com\/wp-content\/uploads\/2025\/09\/EHC-statement-on-VWF-2025-Blog-Banner.jpg?strip=all&sharp=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/comments?post=6159"}],"version-history":[{"count":1,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6159\/revisions"}],"predecessor-version":[{"id":6161,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/posts\/6159\/revisions\/6161"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media\/4831"}],"wp:attachment":[{"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/media?parent=6159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/categories?post=6159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ehc.eu\/hr\/wp-json\/wp\/v2\/tags?post=6159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}